Teratogen-mediated inhibition of target tissue response to Shh signaling

Science

Volumn 280, Issue 5369, 1998, Pages 1603-1607

  Cooper, Michael K ^a,b   Porter, Jeffery A ^b,c   Young, Keith E ^b   Beachy, Philip A ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Ontogeny Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(2 CHLOROBENZYLAMINOMETHYL)CYCLOHEXANE; 4 [2 [1 (4 CHLOROCINNAMYL) 4 PIPERAZINYL]ETHYL]BENZOIC ACID; REGULATOR PROTEIN; SONIC HEDGEHOG PROTEIN; TERATOGENIC AGENT; TRIPARANOL; VERATRUM ALKALOID;

ARTICLE; BIRTH DEFECT; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYCLOPIA; EMBRYO; EMBRYO PATTERN FORMATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TARGET ORGAN; TISSUE REACTION;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CHICK EMBRYO; CHOLESTEROL; CULTURE TECHNIQUES; DNA-BINDING PROTEINS; ENDOPLASMIC RETICULUM; HEDGEHOG PROTEINS; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HOLOPROSENCEPHALY; HOMEODOMAIN PROTEINS; MEMBRANE PROTEINS; MUSCLE PROTEINS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PAX7 TRANSCRIPTION FACTOR; PROTEINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TERATOGENS; TOMATINE; TRANS-1,4-BIS(2-CHLOROBENZAMINOMETHYL)CYCLOHEXANE DIHYDROCHLORIDE; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRIPARANOL; VERATRUM ALKALOIDS;

EID: 0032486433     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.280.5369.1603     Document Type: Article

References (56)

1. C. Chiang et al., Nature 383, 407 (1996).
2. J. L. R. Rubenstein and P. A. Beachy, Curr. Opin. Neurobiol. 8, 18 (1998); M. M. Cohen and K. K. Sulik, J. Craniofacial Genet. Dev. Biol. 12, 196 (1992).
3. J. L. R. Rubenstein and P. A. Beachy, Curr. Opin. Neurobiol. 8, 18 (1998); M. M. Cohen and K. K. Sulik, J. Craniofacial Genet. Dev. Biol. 12, 196 (1992).
4. E. Belloni et al., Nature Genet. 14, 353 (1996); E. Roessler et al., ibid., p. 357.
5. E. Belloni et al., Nature Genet. 14, 353 (1996); E. Roessler et al., ibid., p. 357.
6. J. J. Lee et al., Science 266, 1528 (1994).
7. J. A. Porter et al., Nature 374, 363 (1995).
8. J. A. Porter, K. E. Young, P. A. Beachy, Science 274, 255 (1996).
9. C. Roux, Arch. Fr. Pediatr. 21, 451 (1964); C. R. Soc. Biol. 160, 1353 (1966).
10. C. Roux, Arch. Fr. Pediatr. 21, 451 (1964); C. R. Soc. Biol. 160, 1353 (1966).
11. D. B. Dehart, L. Lanoue, G. S. Tint, K. K. Sulik, Am. J. Med. Genet. 68, 328 (1997); J. Aufenanger, J. Pill, F. H. Schmidt, K. Stegmeier, Biochem. Pharmacol. 35, 911 (1986).
12. D. B. Dehart, L. Lanoue, G. S. Tint, K. K. Sulik, Am. J. Med. Genet. 68, 328 (1997); J. Aufenanger, J. Pill, F. H. Schmidt, K. Stegmeier, Biochem. Pharmacol. 35, 911 (1986).
13. M. Kraml, J. F. Bagli, D. Dvomick, Biochem. Biophys. Res. Commun. 15, 455 (1964); G. Popjáck, A. Meenan, E. J. Parish, W. D. Nes, J. Biol. Chem. 264, 6230 (1989).
14. M. Kraml, J. F. Bagli, D. Dvomick, Biochem. Biophys. Res. Commun. 15, 455 (1964); G. Popjáck, A. Meenan, E. J. Parish, W. D. Nes, J. Biol. Chem. 264, 6230 (1989).
15. R. I. Kelley et al., Am. J. Med. Genet. 66, 478 (1996); G. S. Tint et al., N. Eng. J. Med. 330, 107 (1994).
16. R. I. Kelley et al., Am. J. Med. Genet. 66, 478 (1996); G. S. Tint et al., N. Eng. J. Med. 330, 107 (1994).
17. T. E. Willnow et al., Proc. Natl. Acad. Sci. U.S.A. 93, 8460 (1996); S. Stefansson, D. A. Chappell, K. M. Argraves, D. K. Strickland, W. S. Argraves, J. Biol. Chem. 270, 19417 (1995).
18. T. E. Willnow et al., Proc. Natl. Acad. Sci. U.S.A. 93, 8460 (1996); S. Stefansson, D. A. Chappell, K. M. Argraves, D. K. Strickland, W. S. Argraves, J. Biol. Chem. 270, 19417 (1995).
19. W. Binns, L. F. James, J. L. Shupe, G. Everett, Am. J. Vet. Res. 24, 1164 (1963); R. F. Keeler and W. Binns, Teratology 1, 5 (1968).
20. W. Binns, L. F. James, J. L. Shupe, G. Everett, Am. J. Vet. Res. 24, 1164 (1963); R. F. Keeler and W. Binns, Teratology 1, 5 (1968).
21. P. A. Beachy et al., Cold Spring Harbor Symp. Quant. Biol. 62, 191 (1997).
22. Jervine [250 μl of a sonicated solution (1 mg/ml)] was applied to windowed, fertile chick eggs (White Leghorn, Chestertown, MD) at 14 hours of incubation. After 4 days of further incubation, the embryos were processed for scanning electron microscopy.
23. Embryos at Hamburger and Hamilton stage 9 to 10 (8 to 10 somites) were used for all explant assays [T. Yamada, S. L. Raff, T. Edlund, T. M. Jessell, Cell 73, 673 (1993)]. AY9944 (Wyeth-Ayerst Research, Princeton, NJ), triparanol (Hoechst Marion Roussel, Cincinnati, OH), jervine, cyclopamine, or tomatidine (from W. Gaffield; all compounds were in 10 mM stocks in 95% ethanol, except AY9944, which is water soluble), and purified Shh-N or BMP7 (from H. Reddi) were added at the initiation of the cultures. Control explants were cultured with the maximum ethanol concentration used for drug treatments. All of the explants were cultured for 40 to 48 hours except for assays of Pax7 repression, which were cultured for 20 to 22 hours. Primary antibodies used were HNF3β (K2), Isl1/Isl2 (40.2D6), Pax7 (from S. Morton and T. Jessell), and HNK-1/N-CAM (Sigma Biosciences).
24. E. Marti, R. Takada, D. A. Bumcrot, H. Sasaki, A. P. McMahon, Development 121, 2537 (1995).
25. A. Ruiz i Altaba, M. Placzeck, M. Baldassare, J. Dodd, T. M. Jessell, Dev. Biol. 170, 299 (1995); J. Ericson, S. Thor, T. Edlund, T. M. Jessell, T. Yamada, Science 256, 1555 (1992).
26. A. Ruiz i Altaba, M. Placzeck, M. Baldassare, J. Dodd, T. M. Jessell, Dev. Biol. 170, 299 (1995); J. Ericson, S. Thor, T. Edlund, T. M. Jessell, T. Yamada, Science 256, 1555 (1992).
27. H. Roelink et al., Cell 81, 445 (1995).
28. Induction of HNF3β and Isl1 in midline explants was fully inhibited with 4.0 μM AY9944, 1 μM triparanol, and 1 μM cyclopamine. Intermediate doses of AY9944 (0.5 μM), triparanol (0.25 μM), and cyclonine (0.25 μM) blocked induction of HNF3β while permitting induction of Isl1.
29. W. Gaffield and R. F. Keeler, J. Nat. Toxins 5, 25 (1996).
30. HK293 cells, stably transfected with Shh with the Ecdysone-Inducible Mammalian Expression System (Invitrogen), were cultured to 30 to 40% confluency and then changed to culture medium with 10% delipidated serum [K.M. Gibson et al., J. Lipid Res. 31, 515 (1990)] and insulin-transferrin-sodium selenite media supplement (Sigma). After 24 hours, the cells were induced to express Shh with 1 μM muristerone A (Invitrogen), and AY9944, triparanol, jervine, cyclopamine, or tomatidine was added [see (15)]. After an additional 24 hours, cell lysates were analyzed with 12% SDS-polyacrylamide gels.
31. Chick embryos were treated with ∼10 μM jervine at stage 20 for 8, 16, 24, or 32 hours before fixation and stained with an antibody that recognizes Shh-N. No difference in the normal localization of Shh-N protein to the apical domain of floor plate cells or on the surfaces of commissural axons (16) was seen in treated embryos.
32. 6Hh-C protein was stimulated by 12 μM cholesterol, but this cleavage was neither stimulated nor inhibited by the addition of jervine, cyclopamine, or tomatidine, even at 350 μM.
33. Other sterols that participated in the reaction with similar efficiency to cholesterol are β-sitosterol, 5-androsten-3β-ol, and 7β-hydroxycholesterol. Sterols that participated with reduced efficiency are coprastan-3-ol, ergosterol, 4β-hydroxycholesterol, 19-hydroxycholesterol, 20α-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, and 25-hydroxycholesterol. Epicholesterol, cholesterol acetate, α-ecdysone, 20-OH ecdysone, 3-keto-5-cholestene, and thiocholesterol (3(β)-thiol) were unable to participate in the reaction. The in vitro reaction thus requires an unhindered hydroxyl at the 3β position on a tetracyclic sterol nucleus, although neither the isooctyl side chain nor the number or positions of the double bonds in the sterol nucleus appear to affect autoprocessing critically.
34. J. Ericson, S. Morton, A. Kawakami, H. Roelink, T. M. Jessell, Cell 87, 661 (1996).
35. K. F. Liem, G. Tremml, H. Roelink, T. M. Jessell, ibid. 82, 969 (1995).
36. Jervine (10 μM), cyclopamine (10 μM), and tomatidine (50 μM) all failed to inhibit formation of migratory HNK-1-positive cells, either from ventral neural plate explants cultured with BMP7 (100 ng/ml) or from explanted dorsal neural plate with contiguous epidermal ectoderm (an endogenous source of BMP7).
37. P. W. Ingham, A. M. Taylor, Y. Nakano, Nature 353, 184 (1991); L. V. Goodrich, L. Milenkovic, K. M. Higgins, M. P. Scott, Science 277, 1109 (1997).
38. P. W. Ingham, A. M. Taylor, Y. Nakano, Nature 353, 184 (1991); L. V. Goodrich, L. Milenkovic, K. M. Higgins, M. P. Scott, Science 277, 1109 (1997).
39. G. Gil, J. R. Faust, D. J. Chin, J. L. Goldstein, M. S. Brown, Cell 41, 249 (1985); X. Hua, A. Nohturffl, J. L. Goldstein, M. S. Brown, ibid. 87, 415 (1996); E. D. Carstea et al., Science 277, 228 (1997); S. K. Loftus et al., ibid., p. 232.
40. G. Gil, J. R. Faust, D. J. Chin, J. L. Goldstein, M. S. Brown, Cell 41, 249 (1985); X. Hua, A. Nohturffl, J. L. Goldstein, M. S. Brown, ibid. 87, 415 (1996); E. D. Carstea et al., Science 277, 228 (1997); S. K. Loftus et al., ibid., p. 232.
41. G. Gil, J. R. Faust, D. J. Chin, J. L. Goldstein, M. S. Brown, Cell 41, 249 (1985); X. Hua, A. Nohturffl, J. L. Goldstein, M. S. Brown, ibid. 87, 415 (1996); E. D. Carstea et al., Science 277, 228 (1997); S. K. Loftus et al., ibid., p. 232.
42. G. Gil, J. R. Faust, D. J. Chin, J. L. Goldstein, M. S. Brown, Cell 41, 249 (1985); X. Hua, A. Nohturffl, J. L. Goldstein, M. S. Brown, ibid. 87, 415 (1996); E. D. Carstea et al., Science 277, 228 (1997); S. K. Loftus et al., ibid., p. 232.
43. None of the explant responses to Shh-N were affected by addition of 25-hydroxycholesterol at 25 μM. 25-hydroxycholesterol is a potent inhibitor of HMG CoA reductase and at the concentrations used blocks de novo cholesterol synthesis in chick embryos and in cultured cell systems [S. C. Miller and G. Melnykovych, J. Lipid Res. 25, 991 (1984); J. J. Bell, T. E. Sargeant, J. A. Watson, J. Biol. Chem. 251, 1745 (1976); (37)]. The addition of 25-hydroxycholesterol to explant cultures did not reverse the inhibitory effects of any of the teratogenic compounds.
44. None of the explant responses to Shh-N were affected by addition of 25-hydroxycholesterol at 25 μM. 25-hydroxycholesterol is a potent inhibitor of HMG CoA reductase and at the concentrations used blocks de novo cholesterol synthesis in chick embryos and in cultured cell systems [S. C. Miller and G. Melnykovych, J. Lipid Res. 25, 991 (1984); J. J. Bell, T. E. Sargeant, J. A. Watson, J. Biol. Chem. 251, 1745 (1976); (37)]. The addition of 25-hydroxycholesterol to explant cultures did not reverse the inhibitory effects of any of the teratogenic compounds.
45. H. Yoshikawa, Brain Dev. 13, 115 (1991).
46. Y. Lange and T. L. Steck, J. Biol. Chem. 269, 29371 (1994); Trends Cell Biol. 6, 205 (1996); J. E. Metherall, K. Waugh, H. Li, J. Biol. Chem. 271, 2627 (1996); J. D. Butler, ibid. 267, 23797 (1992).
47. Y. Lange and T. L. Steck, J. Biol. Chem. 269, 29371 (1994); Trends Cell Biol. 6, 205 (1996); J. E. Metherall, K. Waugh, H. Li, J. Biol. Chem. 271, 2627 (1996); J. D. Butler, ibid. 267, 23797 (1992).
48. Y. Lange and T. L. Steck, J. Biol. Chem. 269, 29371 (1994); Trends Cell Biol. 6, 205 (1996); J. E. Metherall, K. Waugh, H. Li, J. Biol. Chem. 271, 2627 (1996); J. D. Butler, ibid. 267, 23797 (1992).
49. Y. Lange and T. L. Steck, J. Biol. Chem. 269, 29371 (1994); Trends Cell Biol. 6, 205 (1996); J. E. Metherall, K. Waugh, H. Li, J. Biol. Chem. 271, 2627 (1996); J. D. Butler, ibid. 267, 23797 (1992).
50. Y. Lange, H. Duan, T. Mazzone, J. Lipid Res. 37, 534 (1996).
51. M. K. Cooper et al., unpublished data.
52. The following class 2 sterol transport inhibitors at the given concentrations blocked the response of intermediate neural plate explants to 25 nM Shh-N, without affecting signaling by BMP7:0.25 μM U 18666A, 50 μM chloroquine, 75 μM imipramine, and 20 μM progesterone.
53. J. Capdevila, P. Pariente, J. Sampedro, J. L. Alonso, I. Guerrero, Development 120, 987 (1994); B. Wang, N. Fuse, J. A. Porter, P. A. Beachy, unpublished data.
54. J. Capdevila, P. Pariente, J. Sampedro, J. L. Alonso, I. Guerrero, Development 120, 987 (1994); B. Wang, N. Fuse, J. A. Porter, P. A. Beachy, unpublished data.
55. M. K. Cooper, J. A. Porter, K. E. Young, P. A. Beachy, data not shown.
56. We thank R. I. Kelley, Y. Lange, D. Leahy, and R. K. Mann for comments on the manuscript; S. Morton and T. Jessell for antibodies; W. Gaffield for plant alkaloids; Wyeth-Ayerst for AY9944; and Hoechst Marion Roussel for triparanol. M.K.C. is a Physician Postdoctoral Fellow and P.A.B. is an investigator of the Howard Hughes Medical Institute.